Available Until 7/1/2024

Evolving Considerations for Prevention and Management of COVID 19—Let’s Not Forget the Immunocompromised Patient!

Content Release Date: 2/8/2023
Expiration Date: 7/1/2024
Activity Type: Application-based
CE Credits: 1.5 contact hours (0.15 CEUs)
Activity Fee:  Free

Activity Overview

This presentation will highlight expert guidance for optimizing treatment and prevention of COVID-19 in the immunocompromised as well as strategies for reaching the target population and provides 1.50 hours of continuing pharmacy education credit.  

Part 1: 

Evolving Considerations for Prevention and Management of COVID 19—Let’s Not Forget the Immunocompromised Patient!* 

COVID-19 continues to pose a significant health risk, especially to those who cannot receive or do not respond to vaccination. As new variants emerge and data become available, it is important for pharmacists to stay abreast of these changes. This presentation will highlight expert guidance for optimizing treatment and prevention of COVID-19 in the immunocompromised as well as strategies for reaching the target population. 


Part 2: 
Living Handout

Available now!

Engaging the Experts Podcasts

Tune in for additional insights and perspectives

from our faculty experts.

CE Credits: 1.5 hours CE Credits: none CE Credits: none

*Please note, this activity was presented live on December 6, 2022 as part of the ASHP 2022 Midyear Clinical Meeting & Exhibition. You can only claim credit once for this activity; live or home study


The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This activity was planned to meet the educational needs of pharmacists who want to optimize treatment and prevention of COVID-19 in the immunocompromised population.

After participating in this CPE activity, learners should be able to:

ACPE Number: 0204-0000-22-423-H01-P

  • Describe the pharmacist’s role in prevention and treatment strategies for immunocompromised patients at risk for COVID-19 infection
  • Discuss the role of pre-exposure prophylaxis in an immunocompromised patient
  • Create a treatment plan for an immunocompromised patient with COVID-19 infection
  • Summarize prevention and management strategies for COVID-19 in immunocompromised pediatric patients 

Katherine Yang, PharmD, MPH, FCSHP
Health Sciences Clinical Professor of Pharmacy
University of California, San Francisco (UCSF) School of Pharmacy
Infectious Diseases Clinical Pharmacist
UCSF Medical Center
San Francisco, California 

Katherine Yang, PharmD, MPH, FCSHP is a Health Sciences Clinical Professor of Pharmacy at the UCSF School of Pharmacy and an infectious diseases clinical pharmacist at the UCSF Medical Center in San Francisco, California. Dr. Yang specializes in the pharmacokinetic and pharmacodynamic optimization of antibiotic dosing for the treatment of multi-drug resistant gram-negative infections. Since the start of the pandemic, Dr. Yang has been heavily involved in the management of COVID-19 therapeutics. 

Monica V. Mahoney PharmD, BCPS, BCIDP, FCCP
Clinical Pharmacy Specialist, Infectious Diseases
Outpatient ID/OPAT Clinics
Beth Israel Deaconess Medical Center
Boston, Massachusetts 

Monica Mahoney, PharmD, BCPS, BCIDP, FCCP is a clinical pharmacy specialist in the outpatient infectious diseases and outpatient parenteral antibiotic therapy clinics at Beth Israel Deaconess Medical Center. Dr. Mahoney received her PharmD degree from Massachusetts College of Pharmacy and Health Sciences in Boston, Massachusetts. She completed postgraduate year 1 residency and postgraduate year 2 infectious diseases residency at Tufts Medical Center in Boston, Massachusetts. She is an active member of many pharmacy and infectious diseases professional organizations, including ASHP, the Society of Infectious Diseases Pharmacists, and the Infectious Diseases Society of America. 
Michael Ganio, Pharm.D., M.S., BCPS, FASHP
Senior Director, Pharmacy Practice and Quality
Bethesda, Maryland

Dr. Ganio joined the staff at ASHP as Director of Pharmacy Practice and Quality in January of 2018. As a member of the Center on Medication Safety and Quality team, his responsibilities span the practice of pharmacy and include drug shortages, pharmaceutical quality, sterile and non-sterile drug compounding practices, hazardous drug handling, and the ASHP Standardize 4 Safety initiative. Dr. Ganio earned his Pharm.D. from the Rutgers University Ernest Mario School of Pharmacy and his Master’s degree in Health-System Pharmacy Administration from The Ohio State University College of Pharmacy. He completed a PGY1 Pharmacy Practice residency at The Ohio State University Wexner Medical Center. Dr. Ganio is a Board Certified Pharmacotherapy Specialist (BCPS) and is a Certified Professional in Healthcare Information and Management Systems (CPHIMS). 

Sarah Parsons, PharmD, BCPPS
Clinical Pharmacy Specialist Pediatric Infectious Diseases
Antimicrobial Stewardship, Cystic Fibrosis
The Children's Hospital of the King's Daughters
Norfolk, Virginia  

Sarah Parsons, PharmD, BCPPS is a clinical pharmacy specialist in pediatric infectious diseases at the Children’s Hospital of the King’s Daughters focusing in antimicrobial stewardship and COVID-19 management in pediatric patients. Dr. Parsons received her Bachelor of Science focused in microbiology and immunology from Radford University followed by her Doctor of Pharmacy Degree from Virginia Commonwealth School of Pharmacy. She completed a postgraduate year 1 residency at HCA Health system in Richmond, Virginia.  

No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company. As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company.

Methods and CE Requirements

Activities can be completed in any order. Each activity consists of audio and video and an evaluation. Learners must review all content and complete an evaluation to receive continuing education credit for each activity.

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

Per ACPE requirements, CPE credit must be claimed within 60 days of being earned – no exceptions! To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, we encourage you to check your NABP eProfile account to validate your credits were transferred successfully before the ACPE 60-day deadline. After the 60 day deadline, ASHP will no longer be able to award credit for this activity.

Provided by ASHP
Supported by an educational grant from AstraZeneca Inc.